Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1)
Authors: Kurzrock, R., Hickish, T., Wyrwicz, L., André, T., Sarosiek, T., Kocsis, J., Nemecek, R., Wu, Q., Mohanty, P., Stecher, M., Simard, J., Dinarello, C.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Volume: 28
eISSN: 1569-8041
DOI: 10.1093/annonc/mdx261.280
Source: Scopus
Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1).
Authors: Kurzrock, R., Hickish, T., Wyrwicz, L., André, T., Sarosiek, T., Kocsis, J., Nemecek, R., Wu, Q., Mohanty, P., Stecher, M., Simard, J., Dinarello, C.
Journal: Ann Oncol
Volume: 28 Suppl 3
eISSN: 1569-8041
DOI: 10.1093/annonc/mdx261.280
Source: PubMed